Roles of Mesenchymal Stromal Cells in the Head and Neck Cancer Microenvironment

Overview

Journal Biomed Pharmacother

Specialties Biology
General Medicine
Pharmacology

Date 2021 Nov 19

PMID 34794230

Citations 10

Authors

Marcelo Coutinho de Miranda

Mariane Izabella Abreu de Melo

Pricila da Silva Cunha

Jovino Gentilini Junior

Jerusa Araujo Quintao Arantes Faria

Michele Angela Rodrigues

Dawidson Assis Gomes

Affiliations

Soon will be listed here.

Abstract

Head and neck cancer (HNC), a common malignancy worldwide, is associated with high morbidity and mortality rates. Squamous cell carcinoma is the most common HNC type, followed by salivary gland carcinomas, head and neck sarcomas, and lymphomas. The microenvironment of HNCs comprises various cells that regulate tumor development. Recent studies have reported that the tumor microenvironment, which modulates cancer progression, regulates cancer treatment response. However, the presence of different types of stromal cells in cancers is a major challenge to elucidate the role of individual cells in tumor progression. The role of mesenchymal stromal cells (MSCs), which are a component of the tumor microenvironment, in HNC is unclear. The major impediment for characterizing the role of MSCs in cancer progression is the lack of MSC-specific markers and their phenotypic similarity with stromal cells. This review aimed to summarize the latest findings on the role of MSCs in the progression of HNC to improve our understanding of HNC pathophysiology.

Citing Articles

A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signaling.

Ferrara Y, Latino D, Costagliola di Polidoro A, Oliver A, Sarnella A, Caprio M Cell Commun Signal. 2025; 23(1):74.

PMID: 39930439 PMC: 11809099. DOI: 10.1186/s12964-025-02073-7.

Role of Mesenchymal Stem/Stromal Cells in Head and Neck Cancer-Regulatory Mechanisms of Tumorigenic and Immune Activity, Chemotherapy Resistance, and Therapeutic Benefits of Stromal Cell-Based Pharmacological Strategies.

Starska-Kowarska K Cells. 2024; 13(15.

PMID: 39120301 PMC: 11311692. DOI: 10.3390/cells13151270.

Genomic and single-cell characterization of patient-derived tumor organoid models of head and neck squamous cell carcinoma.

Um J, Zheng Y, Mao Q, Nam C, Zhao H, Koh Y bioRxiv. 2024; .

PMID: 39005427 PMC: 11244938. DOI: 10.1101/2024.06.28.601068.

Role of Microenvironmental Components in Head and Neck Squamous Cell Carcinoma.

Jumaniyazova E, Lokhonina A, Dzhalilova D, Kosyreva A, Fatkhudinov T J Pers Med. 2023; 13(11).

PMID: 38003931 PMC: 10672525. DOI: 10.3390/jpm13111616.

MTDH enhances radiosensitivity of head and neck squamous cell carcinoma by promoting ferroptosis based on a prognostic signature.

Cao X, Ge Y, Yan Z, Hu X, Peng F, Zhang Y J Radiat Res. 2023; 65(1):10-27.

PMID: 37981296 PMC: 10803166. DOI: 10.1093/jrr/rrad074.

References

Steingen C, Brenig F, Baumgartner L, Schmidt J, Schmidt A, Bloch W . Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Mol Cell Cardiol. 2008; 44(6):1072-1084. DOI: 10.1016/j.yjmcc.2008.03.010. View

Ji X, Zhang Z, Han Y, Song J, Xu X, Jin J . Mesenchymal stem cells derived from normal gingival tissue inhibit the proliferation of oral cancer cells in vitro and in vivo. Int J Oncol. 2016; 49(5):2011-2022. DOI: 10.3892/ijo.2016.3715. View

Mishra P, Banerjee D . Activation and Differentiation of Mesenchymal Stem Cells. Methods Mol Biol. 2017; 1554:201-209. DOI: 10.1007/978-1-4939-6759-9_13. View

Worthley D, Churchill M, Compton J, Tailor Y, Rao M, Si Y . Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell. 2015; 160(1-2):269-84. PMC: 4436082. DOI: 10.1016/j.cell.2014.11.042. View

Reichart P, Philipsen H, Sonner S . Ameloblastoma: biological profile of 3677 cases. Eur J Cancer B Oral Oncol. 1995; 31B(2):86-99. DOI: 10.1016/0964-1955(94)00037-5. View

Bianco P . "Mesenchymal" stem cells. Annu Rev Cell Dev Biol. 2014; 30:677-704. DOI: 10.1146/annurev-cellbio-100913-013132. View

Lv F, Tuan R, Cheung K, Leung V . Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014; 32(6):1408-19. DOI: 10.1002/stem.1681. View

Halvorsen Y, Wilkison W, Gimble J . Adipose-derived stromal cells--their utility and potential in bone formation. Int J Obes Relat Metab Disord. 2000; 24 Suppl 4:S41-4. DOI: 10.1038/sj.ijo.0801503. View

Segers V, Van Riet I, Andries L, Lemmens K, Demolder M, De Becker A . Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. Am J Physiol Heart Circ Physiol. 2005; 290(4):H1370-7. DOI: 10.1152/ajpheart.00523.2005. View

10.

Geiger T, Peeper D . Metastasis mechanisms. Biochim Biophys Acta. 2009; 1796(2):293-308. DOI: 10.1016/j.bbcan.2009.07.006. View

11.

Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E . Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood. 2008; 112(13):4991-8. DOI: 10.1182/blood-2008-07-166892. View

12.

Tlsty T, Coussens L . Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2007; 1:119-50. DOI: 10.1146/annurev.pathol.1.110304.100224. View

13.

Ng J, Iyer N, Tan M, Edgren G . Changing epidemiology of oral squamous cell carcinoma of the tongue: A global study. Head Neck. 2016; 39(2):297-304. DOI: 10.1002/hed.24589. View

14.

Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter G . Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med. 2007; 357(25):2543-51. DOI: 10.1056/NEJMoa071825. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Salo S, Bitu C, Merkku K, Nyberg P, Bello I, Vuoristo J . Human bone marrow mesenchymal stem cells induce collagen production and tongue cancer invasion. PLoS One. 2013; 8(10):e77692. PMC: 3804615. DOI: 10.1371/journal.pone.0077692. View

17.

Horwitz E, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini F . Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005; 7(5):393-5. DOI: 10.1080/14653240500319234. View

18.

Taddei M, Giannoni E, Comito G, Chiarugi P . Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013; 341(1):80-96. DOI: 10.1016/j.canlet.2013.01.042. View

19.

Kfoury Y, Scadden D . Mesenchymal cell contributions to the stem cell niche. Cell Stem Cell. 2015; 16(3):239-53. DOI: 10.1016/j.stem.2015.02.019. View

20.

Gang E, Bosnakovski D, Figueiredo C, Visser J, Perlingeiro R . SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood. 2006; 109(4):1743-51. DOI: 10.1182/blood-2005-11-010504. View